Skip to main content
Clinical Trials/NCT06821373
NCT06821373RecruitingNot Applicable

Developing and Evaluating a Low-intensity Secondary Theory-based Chatbot Intervention to Reduce Common Digital Addictions, Sedentary Behaviors and Mental Distress Among Adolescents: a Randomized Controlled Trial

Chinese University of Hong Kong1 site in 1 country330 target enrollmentStarted: September 1, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
330
Locations
1
Primary Endpoint
Composite score of IGD and SMA

Study Overview

Brief Summary

The goal of the study is to investigate the efficacy of a secondary low-intensity stage of change (SoC) and motivational interviewing (MI)-based Chatbot-assisted intervention in reducing digital addictions in adolescents with Internet gaming disorder (IGD) and/or social media addiction (SMA) by conducting a RCT.

Hypothesis: The intervention group will show a greater reduction in rates of IGD and/or SMA at post-treatment and 3-month follow-up than the control group.

Design and subjects: A two-armed RCT between the intervention group and psycho-educational control group for adolescents aged 10-19 with excessive screen time. Screening, baseline, post-programme, and 3-month follow-up evaluations will be conducted.

Participants will:

Be randomly assigned to online brief intervention or psycho-educational control

Complete questionnaires evaluating 1 ) Primary outcomes (IGD, SMA), 2) Secondary outcomes (sedentary lifestyle, mental distress, quality of life, eHealth literacy) and 3) Mediators/mechanisms (autonomy, competence)

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Single (Participant)

Eligibility Criteria

Ages
10 Years to 19 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Students at grades 5-6 in primary schools or grades 7-12 in secondary schools,
  • •Positive screening results of IGD and/or SMA) based on the validated screening tools
  • •Using smartphone or Internet on a daily base, 4) students' and parental consent,
  • •Chinese speaking.

Exclusion Criteria

  • •Current use of any psychotropic medication.

Arms & Interventions

Control

Sham Comparator

Participants will receive educational but not SoC and MI-based materials about excessive digital use, IGD, and SMA. Such psycho-educational interventions are widely used in behavioral/mental health promotion and have been demonstrated to be effective in increasing knowledge and awareness of behavioral and mental problems. Based on a comprehensive literature review and our previous psycho-educational programs for behavioral/mental health promotion, the research team will design the psycho-educational materials. Themes include definitions, factors, and health consequences of excessive digital use, IGD, and SMA, information on healthy lifestyles, self-regulation skills, and help-seeking resources.

Intervention: Control (Behavioral)

Chatbot

Experimental

The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.

Intervention: Chatbot (Behavioral)

Outcomes

Primary Outcomes

Composite score of IGD and SMA

Time Frame: From enrollment to end of follow-up at 3 months.

Composite outcome of IGD score and SMA score: we define a simple composite as the sum of the two outcomes. Because each outcome measure uses a different scale and has different statistical properties, we will standardize the two variables (i.e., scores of IGD and SMA) first, and then combine the two standardized scores of the outcomes into a composite.

Internet gaming disorder (IGD)

Time Frame: From enrollment to the end of follow-up at 3 months

IGD symptoms are assessed using the Nine-Item Internet Gaming Disorder Scale-Short Form (IGDS9-SF) consists of nine questions that assess IGD symptoms, including preoccupation, tolerance, withdrawal, unsuccessful attempts to limit gaming, deception or lies about gaming, loss of interest in other activities, use despite knowledge of harm, use for escape or relief of negative mood, and harm. The response options for each item include "yes=1" and "no=0". The overall score of the scale ranges from 0 to 9, with a higher score implying a higher level of IGD symptoms. Participants with score ≥ 5 will be classified as having probable IGD.

Social media addiction (SMA)

Time Frame: From enrollment to end of follow-up at 3 months

SMA is defined as excessive use of social media with the addictive symptoms like mood modification, salience, tolerance, withdrawal symptoms, conflict, and relapse. The symptoms of SMA will be measured by the 6-item Bergen Social Media Addiction Scale (BSMAS) based on the six core components of addictive behaviors, including cognitive salience, tolerance, mood modification, difficulty in regulating use, withdrawal, and interference with role performance. The items are rated using a Likert type scale ranging between 1 (very rarely) and 5 (very often). A higher sum score in the BSMAS indicates a greater likelihood of being at risk of developing social media addiction. A cut-off score over 19 indicates probable SMA.

Secondary Outcomes

  • Sedentary lifestyle(From enrollment to end of 3 months follow-up)
  • Entertainment screen time(From enrollment to end of follow-up at 3 months)
  • Health-related Quality of life(From enrollment to end of follow-up at 3 months)
  • Mental distress(From enrollment to end of follow-up at 3 months)
  • eHealth literacy(From enrollment to end of follow-up at 3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Xue YANG

Assistant Professor

Chinese University of Hong Kong

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Estudio fase II prospectivo para evaluar alteraciones en biomarcadores moleculares y la administración de trastuzumab tras progresión a la exposición inicial de trastuzumab-taxano en pacientes diagnosticadas de cáncer de mama metastásico HER2-positivoA prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment - SHERsigTratamiento de pacientes con cáncer de mama metastásico HER2-positivo Treatment of patients with HER2-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancer
EUCTR2008-004013-94-ESF. Hoffmann-La Roche Ltd.50
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaModerate ThrombocytopeniaMyelofibrosisMild Thrombocytopenia
NCT05980806Karyopharm Therapeutics Inc58
Active, not recruiting
Phase 1
A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment - SHERsigTreatment of patients with HER2-positive metastatic breast cancerMedDRA version: 9.1 Level: LLT Classification code 10065430 Term: HER-2 positive breast cancer
EUCTR2008-004013-94-GBF. Hoffmann-La Roche Ltd.50
Active, not recruiting
Not Applicable
A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial exposure to trastuzumab-taxane based treatment - SHERsigTreatment of patients with HER2-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancer
EUCTR2008-004013-94-SEF. Hoffmann-La Roche Ltd.50
Not yet recruiting
Not Applicable
Responsiveness and Minimal Important Change of Two Measures of Pain Intensity in People With Low Back PainLow Back Pain
NCT06270069International Institute of Behavioral Medicines150